|Bid||25.02 x 900|
|Ask||25.23 x 1000|
|Day's Range||24.85 - 26.38|
|52 Week Range||19.08 - 36.15|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Quanterix Corporation to Release Fourth Quarter 2019 Financial Results on March 9, 2020 and Present at Multiple Upcoming Healthcare Conferences
New CARE Consortium study applies ultra-sensitive biomarker solution to validate serum markers as objective indicators of mild traumatic brain injury.
Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been recognized with the Entrepreneur Of The Year® 2019 Award in the New England region by EY. The award acknowledges Hrusovsky’s achievements in healthcare technology innovation, Quanterix’ outstanding financial performance, and his personal commitment to improving precision health. “We are honored to be recognized by EY,” said Hrusovsky.
Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications.
Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that it issued approximately 2.2 million shares of common stock last week, raising $49.7 million in gross proceeds. Additionally, Quanterix will unveil its Simoa HD-X Analyzer™, at the BIO International Convention, in Philadelphia, during a presentation by its Chairman and CEO, Kevin Hrusovsky, taking place June 5 at 10:45 a.m., EDT, in Theater 3. Quanterix is re-engineering ultra-sensitivity with the launch of the HD-X, its latest fully automated Simoa bead-based immunoassay instrument model.
Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters to a brand new, state-of-the-art facility in Billerica, Mass. Brought on by Quanterix’ rapid growth, the move will allow the Company to unite its CLIA-certified laboratory with its expanding workforce to accelerate entry into pharmaceutical drug services and further increase its impact on the transformation of precision healthcare. “We experienced considerable success in our former facilities, launching several new biomarker technologies that are beginning to disrupt drug development and drug approval methodologies, acquiring Aushon to accelerate our entry into Biopharma services and leading a successful public offering in December 2017,” said Kevin Hrusovsky, Chairman and CEO, Quanterix.
Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant Program. Designed to help facilitate breakthroughs in science and medicine, this year’s Accelerator Grant Program will award up to $50,000 toward the cost of research in Quanterix’ Accelerator Lab to help advance the most exciting biomarker research using Quanterix’ ultrasensitive Simoa technology.